GENFIT S.A Current Ratio 2019-2021 | GNFT

GENFIT S.A current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
GENFIT S.A Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.15B $0.04B 3.92
2020-12-31 $0.21B $0.04B 5.95
2020-06-30 $0.26B $0.05B 5.71
2019-12-31 $0.33B $0.05B 6.66
2019-06-30 $0.34B $0.05B 6.45
2018-12-31 $0.26B $0.05B 5.56
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.165B $0.009B
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76